| Bioactivity | Aβ1-42 aggregation inhibitor 1 inhibits AChE (acetylcholinesterase) and BuChE (butyrylcholinesterase) with the IC50 value of 2.64 μM and 1.29 μM, respectively. Aβ1-42 aggregation inhibitor 1 inhibits self-mediated Aβ1-42 aggregation by 51.29% at a concentration of 25 μM. Aβ1-42 aggregation inhibitor 1 has the potential for the research of anti-Alzheimer's disease[1]. |
| Target | IC50: 2.64 μM (AChE), 1.29 μM (BuChE). |
| Invitro | Aβ1-42 aggregation inhibitor 1 (compound 50) (25 μM, 30 min) can selectively form ligand-Cu 2+ complexes with Cu2+[1]. |
| Name | Aβ1–42 aggregation inhibitor 1 |
| CAS | 2439107-75-0 |
| Formula | C29H32N4S |
| Molar Mass | 468.66 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Dushyant V Patel, et al. Novel carbazole-stilbene hybrids as multifunctional anti-Alzheimer agents. Bioorg Chem. 2020 Aug;101:103977. |
Aβ1–42 aggregation inhibitor 1
CAS: 2439107-75-0 F: C29H32N4S W: 468.66
Aβ1-42 aggregation inhibitor 1 inhibits AChE (acetylcholinesterase) and BuChE (butyrylcholinesterase) with the IC50 val
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.